Podcasts about ridgeback biotherapeutics

Viper venom may help fight coronavirus: study Brazilian researchers have found that a molecule in the venom of a type of snake inhibited coronavirus reproduction in monkey cells, a possible first step toward a drug to combat the virus causing COVID-19. A study published in the scientific journal Molecules in August found that the molecule produced by the jararacussu pit viper inhibited the virus's ability to multiply in monkey cells by 75%. The molecule is a peptide, or chain of amino acids, that can connect to an enzyme of the coronavirus PLPro without hurting other cells. The enzyme it connects to is vital to the virus's reproduction. The jararacussu is one of the largest snakes in Brazil. (Reuters) Merck pills may prevent COVID-19 deaths An experimental antiviral pill developed by Merck & Co. could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated. If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19. Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide. (Reuters) These articles were provided by The Japan Times Alpha.

The Bill Kelly Show Podcast: Dominic Barton, a strong advocate for increased trade with China during his term as ambassador, is stepping down amidst growing pressure from the administration of U.S. President Joe Biden for Ottawa to take a tougher stance with Beijing, foreign policy and national security experts said. Barton, who was appointed by the Trudeau government in September 2019, announced his resignation Monday, citing his success “working to secure the release” of Canadians Michael Kovrig and Michael Spavor as the fulfillment of a priority mission handed to him by Prime Minister Justin Trudeau. ALSO: Canada should join diplomatic boycott of Beijing Winter Olympics says O'Toole GUEST: Dr. Lori Turnbull, Director of the School of Public Administration with Dalhousie University - Are the new Canadian travel restrictions clear? Do travelers know what is expected of them? Are airports concerned with the impact of Omicron during the busy travel season? We saw what happened with the land border - no one knew what to do. ALSO: Most Canadians support strong travel restrictions amid Omicron COVID-19 variant: Poll GUEST: Daniel-Robert Gooch, President of the Canadian Airports Council - The federal government will hand over thousands of previously undisclosed residential school documents to the National Centre for Truth and Reconciliation. In an interview, Crown-Indigenous Relations Minister Marc Miller said the government has come to the conclusion that continuing to withhold the documents is a breach of Ottawa's “moral duty” to survivors of the schools. GUEST: Dr. Dawn Lavell-Harvard, Director at the First Peoples House of Learning at Trent University - Merck Canada announced on Monday that it is partnering with Thermo Fisher Scientific to manufacture its COVID-19 antiviral drug in Canada for global distribution in a deal Ottawa hopes will help jump-start the country's position as a biomanufacturing centre and better secure its supply chain for future public health emergencies. The existing Thermo Fisher facility in Whitby, Ont. will produce doses of molnupiravir, an investigational drug developed in collaboration with Ridgeback Biotherapeutics, for distribution in Canada, the U.K., the European Union, Asia Pacific, and Latin America, pending approvals in those respective regions. The drug is awaiting approval by Health Canada. GUEST: Marvin Ryder, Professor with the DeGroote School of Business at McMaster University See omnystudio.com/listener for privacy information.

Plus: Merck, Ridgeback Biotherapeutics say Covid-19 pill was less effective than reported earlier. Russian authorities open probe into coal-mine explosion that killed more than 50. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Two new anti-viral pills have been shown to be safe and effective against COVID in clinical trials, according to recent press releases. The drugs, molnupiravir, developed by Merck and Ridgeback Biotherapeutics, and Paxlovid, developed by Pfizer both appear to significantly reduce hospitalisation in people with early COVID. Some researchers are quietly hopeful that these new weapons in the anti-COVID arsenal could have a big impact, in particular in parts of the world where vaccines are still not widely available, but there are a number of caveats. In this episode of Coronapod, we open the pill boxes and pick through the contents - asking how the drugs work, what side effects we might see and how, if at all, they might change the course of the pandemic.News: COVID antiviral pills: what scientists still want to knowSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. See acast.com/privacy for privacy and opt-out information.

Nota principal Hay epidemias causadas naturalmente y epidemias causadas por bioterrorismo que incluso podrían ser mucho peores de lo que experimentamos hoy y, sin embargo, los avances en la ciencia médica deberían brindarnos herramientas que, ya sabes, podríamos mejorar dramáticamente. Los efectos del cambio climático podrían impactar ya al 85% de la población mundial. A esa conclusión llegó un equipo de investigadores que analizó cerca de 100.000 estudios publicados entre 1951 y 2018, relativos al calentamiento del clima, con la ayuda de sistemas informáticos. Pandemia La Agencia Reguladora de Medicamentos y Productos Sanitarios del Reino Unido dijo este jueves que había autorizado el antiviral oral de Merck y Ridgeback Biotherapeutics, el molnupiravir, para tratar casos de covid-19 Política Irán publicó un video de un supuesto enfrentamiento con la marina de Estados Unidos que habría ocurrido el mes pasado en el Golfo de Omán. Irán afirma que las fuerzas estadounidenses intentaban abordar un petrolero para confiscar el crudo iraní. Economia La farmacéutica estadounidense Pfizer anunció este martes 2 de noviembre que su beneficio acumulado en los primeros nueve meses de 2021 ha aumentado un 124% respecto al mismo tramo del año pasado, gracias en buena parte a las ventas de su vacuna contra el coronavirus. Sociedad Los comandantes del submarino de propulsión nuclear de EE.UU. USS Connecticut que chocó contra un monte subacuático en el Indo-Pacífico el pasado 2 de octubre fueron despedidos de sus cargos por pérdida de confianza, Final noticias purumpumpum y muchas más noticias que importan (y algunas que no tanto) Episodio #35 Temporada 4 dale like a la página para quedarte en contacto con @LRDFDM Música de comienzo : Lucho MC https://fb.watch/91prcgTvo4/ Radio Revolución : https://revolucion989.com.ar 98.9 podcast : www.cabinadigital.com Sitio Web : http://blendenblick.com Facebook: https://www.facebook.com/LRDFDM Instagram : https://www.instagram.com/lrdfdm/ Twitter : https://twitter.com/laradiodelfind1 Bitchute :https://www.bitchute.com/channel/4A23L8lB9c8m/ LBRY : https://lbry.tv/@LRDFDM:1 Tumblr: https://lrdfdm.tumblr.com/ Babel : https://babel.superocho.org/LRDFDM Podcast : Ivoox: https://de.ivoox.com/es/escuchar-blenden-blick_nq_295679_1.html Anchor : https://anchor.fm/lrdfdm Breaker ,Google podcast, Overcast, Pocket Cast, RadioPublic, Spotify

Medicamento molnupiravir, produzido pela farmacêutica MSD e Ridgeback Biotherapeutics, teve a primeira autorização para ser utilizado contra a doença.

Medicamento molnupiravir, produzido pela farmacêutica MSD e Ridgeback Biotherapeutics, teve a primeira autorização para ser utilizado contra a doença.

(LONDON) —Pharmaceutical company Merck agreed to allow other drug makers to produce its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access to the potentially life-saving drug, a United Nations-backed public health organization said on Wednesday. The Medicines Patent Pool said in a statement that it had signed a voluntary licensing agreement for molnupiravir with Merck and its partner Ridgeback Biotherapeutics.

A new pill, molnupiravir, from Ridgeback Biotherapeutics. and partner Merck & Co. could cut hospitalizations and deaths from COVID-19 in half. The companies are already seeking emergency use authorization in the U.S. and global governments are pledging to buy big lots of the medicine, pending regulatory approvals.But some people are already crying foul over the proposed price, $712 for a treatment, which includes twice daily doses for five days – because the U.S. government helped pay for the research. Molnupiravir was invented at Emory University and had partial funding and support from the U.S. government.Joseph Allen, executive director of the Bayh-Dole Coalition, joined the BioWorld Insider Podcast this week to explain how this scientific discovery may have never had a chance to move out of the university onto pharmacy shelves without the government's support of innovation. The cost of health care, including drugs, is an entirely separate topic and should be treated as such, he said. Allen explained that the Bayh-Dole Act, which then-Senator Joe Biden voted for in 1980, also has something called a march-in provision. In the absence of good-faith efforts being made to commercialize an invention discovered with government support, it enables the government to force licensing of the technology to another party. While some have argued the same mechanism could be used to set the price of federally funded medicines, Allen said that's never been the law's intention. However, the pricing saga plays out, the pill would be a far more convenient alternative to other currently used therapies which are injected.Listen to BioWorld Insider podcast to better understand the controversial story behind the story. See acast.com/privacy for privacy and opt-out information.

Drugmaker Merck said Monday its seeking FDA emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir. It comes in capsule form. If authorization is granted, the drug, made by Merck and Ridgeback Biotherapeutics, would be the first oral antiviral treatment to fight Covid-19.To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Merck and partner Ridgeback Biotherapeutics have asked the FDA to approve their Covid-19 antiviral pill molnupiravir for emergency use. It's only the latest in a stream of biotech innovation this year; Dr. Christiana Bardon, co-managing partner of one of the world's largest biotech investment firms MPM BioImpact Capital, discusses the sector's opportunities for portfolios and public health right now. The global energy crisis has sent crude oil to over $80 a barrel, and vice chairman of IHS Markit Dan Yergin says its coming for politicians in Washington, D.C. Plus, Southwest Airlines faces a tough day on Wall Street after mass cancelations over the weekend, and William Shatner is going to space--at the young age of 90. In this episode:Dr. Christiana Bardon, @MPMCapitalDan Yergin, @DanielYerginJoe Kernen, @JoeSquawkBecky Quick, @BeckyQuick

Jim Cramer and David Faber led off the show with a look at what investors should do in wake of the recent rally in energy prices: WTI crude surging to a seven-year high and natural gas up 50% over the past three months. The anchors highlighted Goldman Sachs lowering its U.S. growth forecasts for 2021 and 2022 as the firm expects a "delayed recovery in consumer spending" and no improvement in the global chip supply until next year. Jim and David also discussed a rough start for Southwest: Shares under pressure after the airline announced hundreds of additional flight cancellations on top of the 1,800 that took place over the weekend, citing bad weather, air traffic control issues and staff shortages. Southwest also disputes speculation that its high level of cancellations compared to other airlines were due to employee protests of a COVID-19 vaccine mandate. Speaking of the pandemic, Merck and Ridgeback Biotherapeutics announced submission of an emergency use authorization application to the FDA for their oral COVID-19 treatment. The anchors reacted to what former FDA Commissioner Dr. Scott Gottlieb told CNBC about when he believes Merck's COVID pill will hit the markets. Changes at the top of KKR: Co-founders Henry Kravis and George Roberts stepped down as Co-CEOs of the private equity firm. The anchors explored what this means for KKR and the world of P.E. Also in focus: Big banks kicking off earnings season later this week, Chinese stocks continue to rebound, Emerson Electric's $11-billion merger deal with Aspen Technology, and as movie theaters look to rebound from the pandemic -- the new James Bond film "No Time To Die" debuts by grossing $56-million at the box office domestically. It was the weekend's top performer but just shy of consensus estimates.

La compañía estadounidense Merck publicó el viernes 1 de octubre de 2021 en su página de internet, un estudio donde mostró un nuevo medicamento para suministro oral que aminora la cantidad de fallecimientos e internaciones de pacientes con coronavirus. El análisis planificado de 775 pacientes arrojó que solamente el 7,3% de los que recibieron el molnupiravir fueron hospitalizados o murieron 29 días después del tratamiento, una cifra más satisfactoria que el 14,1% de los que tomaron un placebo. Además, no hubo muertes en el grupo de la píldora de Merck y sí hubo ocho personas que fallecieron con el placebo. Que es el molnupiravir: El molnupiravir es una forma experimental administrada por vía oral de un potente análogo de ribonucleósido. Para qué sirve el molnupiravir: Inhibe la replicación del SARS-CoV-2, el agente causante del COVID-19. Se ha demostrado que molnupiravir es activo en varios modelos preclínicos de SARS-CoV-2, incluso para la profilaxis, el tratamiento y la prevención de la transmisión. Además, los datos preclínicos y clínicos han demostrado que molnupiravir es activo contra las variantes más comunes del SARS-CoV-2. Quien se inventó el molnupiravir: El molnupiravir se inventó en Drug Innovations at Emory (DRIVE), LLC, una empresa de biotecnología sin fines de lucro propiedad en su totalidad de Emory University, y está siendo desarrollado por Merck & Co., Inc. en colaboración con Ridgeback Biotherapeutics. Como se suministró el molnupiravir: El molnupiravir se suministró una píldora cada 12 horas durante cinco días. Todos los sujetos tenían un factor de riesgo como obesidad o edad avanzada. REFERENCIA. https://s2.q4cdn.com/584635680/files/doc_news/Merck-and-Ridgebacks-Investigational-Oral-Antiviral-Molnupiravir-Reduced-the-Risk-of-Hospitalization-or-Death-by-Approximately-50-Per-C1CSM.pdf https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

  Vidcast:  https://youtu.be/wrNvC96y3a4   The media has been heralding the development of molnupiravir, an oral anti-viral agent developed by Merck and Ridgeback Biotherapeutics, that reduced the incidence of hospitalization and death for CoVid patients by about 50%.  Let's look at the fine print about this drug.     The 50% number comes from a Merck phase 3 randomized, controlled, double-blind multi-site global trial of molnupiravir which was stopped at the 90% recruitment level due to “compelling results.” Those participating had positive CoVid PCR tests, mild-to-moderate infections, at least one complicating risk factor such as obesity, diabetes, or older age and began the drug within 5 days of symptom onset.   This orally administered drug inhibits viral replication by causing local mutations in the viral RNA.  While those in the study did not have any worrisome short-term adverse effects, details of side effects of the drug have not been released and there is the possibility that molnupiravir could mutate a patient's DNA with catastrophic results.  For this reason, those in the trial were warned to abstain from sex and to use contraception.   This drug was previously tried in hospitalized CoVid patients without a significant clinical benefit.  It does seem to work earlier in the infection cycle, but there may well be a limited number of days after infection during which it will benefit a patient.  And when it is of use, there is only a 50-50 chance you will be helped.   This drug may turn out to be safe and useful, but for now buyer beware.  If it is proven useful, it will be added to drugs such as monoclonal antibody cocktails and Remdesivir for early disease and dexamethasone and tocilizumab for later disease.  The best defense, though,  is prevention with a CoVid vaccine…. so get vaccinated.   https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/   https://www.sciencemediacentre.org/expert-reaction-to-interim-analysis-of-oral-antiviral-molnupiravir/   #molnupiravir #CoVid #mutagenesis   

In this episode, Ayesha talks about the CDC's updated guidance according to which the COVID-19 vaccines can be administered at the same time as the flu shot and other vaccines. The new guidelines comes after the federal health agency says there is now substantial data around the COVID-19 vaccines to show that it is safe to be administered alongside other vaccines. Additionally, studies show that immunization against influenza may protect against severe symptoms of COVID-19.The editorial team also discussed the stellar trial results of Merck's oral antiviral COVID-19 treatment molnupiravir. Last week Merck released interim data from a Phase III trial of the drug, which showed that it can cut the risk of hospitalizations and deaths by 50 percent. The results were so strong that the independent committee monitoring the trial suggested that the trial could be stopped. The team discussed the convenience of an oral pill treatment for COVID-19, and and how certain factions of the public appear to be less hesitant over COVID-19 treatments compared to COVID-19 vaccines.   Read the full articles here: CDC Says You Can Get Flu and COVID-19 Shots at the Same Time Merck's Oral Pill Molnupiravir Cuts Risk of Hospitalizations and Deaths by Half in COVID-19 Patients For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

진행자: 고준태, Brolley Genster1. S. Korea's hope for normalization boosted with positive trial results from Merck요약: 미국 글로벌 제약사 머크가 개발한 코로나19 경구용 치료제 후보물질 ‘몰누파라비르'의 긍정적인 연구결과에 ‘위드 코로나'로 갈 수 있는 분기점이 마련될 전망이다. 정부는 경구용 치료제 도입을 위해 올해 추경을 통해 1만8000명분의 예산을 확보한 바 있다.[1] South Korea's plan to step into a phased recovery back to normal life in November is gaining support with positive clinical test results of an experimental COVID-19 oral medication overseas. *phased: 단계적인*overseas: (특히 바다로 분리된) 해외, 국외의[2] Leading global drugmaker Merck & Co announced Friday that its experimental antiviral pill dubbed molnupiravir was shown to halve the chances of hospitalization or death for those infected with COVID-19.*experimental: 실험적인, 실험의*dub: (이름, 별명, 명칭을) 주다, 붙이다 [3] Merck and its partner Ridgeback Biotherapeutics reported that 7.3 percent of patients who received molnupiravir died or were either hospitalized by 29 days after receiving the oral antiviral medicine, as opposed to 14.1 percent for placebo-administered patients. No COVID-19 patient died after taking molnupiravir, compared to 8 deaths reported from the placebo group, the firms added.*placebo: 플라세보, 속임약, 위약*administer: 관리하다, 집행하다, 주다 [4] The pill works by blocking the virus from replicating, as does some Acquired Immune Deficiency Syndrome drugs by inhibiting the replication of human immunodeficiency virus. If approved, it would be the first oral antiviral treatment against COVID-19 on the market.*replicate: 모사하다, 복제하다*inhibit: 억제하다, 저해하다기사 원문: http://www.koreaherald.com/view.php?ud=20211002000066 2. Air Force sets up crime unit after sex abuse case요약: 공군이 기존 군사경찰단이 맡던 수사 업무를 독립적으로 전담하도록 본부 직할로 ‘수사단'을 창설했다고 밝혔다. 이번 조치는 5월 발생한 성추행 피해 공군 부사관 사망 사건 당시 피해자 소속 부대 군사경찰의 부실한 초동수사가 드러나면서 논란이 된 이후 이루어졌다.[1] The Air Force on Friday set up a unit of investigators at its headquarters following accusations that cover-ups led to the suicide of a master sergeant who claimed to have been sexually assaulted.*accusation: 혐의, 비난, 고발*cover-up: 은폐, 공작 [2] The unit will take away military police power to investigate crimes, as they have been accused of looking the other way when the master sergeant filed a complaint. The sergeant's death sparked a public outcry that led the military to form an independent investigation arm.*file: 제기하다, 제출하다*outcry: (대중들의) 격렬한 반응, 항의 [3] Military police will no longer be able to look at crimes, but they will carry on policing their bases. The new unit will run a central command at the Air Force headquarters, five regional offices and a forensics department.*police: 치한을 유지하다, 감시하다*forensics: 법의학적인, 범죄 과학 수사의 [4] Meanwhile, the family of the master sergeant said the military should name a special prosecutor to investigate her death, noting the prosecutor should be a civilian. The military appointed a military prosecutor to run the investigation. But it has been neither thorough nor effective, according to the family.*civilian: 민간인*appoint: 임명하다, 지명하다기사 원문: http://www.koreaherald.com/view.php?ud=20211001000646 See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

DrugMaker Merck, announces COVID-19 Pill - Can be taken at home.Subscribe: https://thingsyoushouldknow.supercast.techFacebook: https://www.facebook.com/groups/879254746173653In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.If cleared by regulators, it would be the first pill shown to treat COVID-19, adding a whole new, easy-to-use weapon to an arsenal that already includes the vaccine.The company said it will soon ask health officials in the U.S. and around the world to authorize the pill's use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if it gets the OK, could be distributed quickly soon afterward.All other COVID-19 treatments now authorized in the U.S. require an IV or injection. A pill taken at home, by contrast, would ease pressure on hospitals and could also help curb outbreaks in poorer and more remote corners of the world that don't have access to the more expensive infusion therapies.“This would allow us to treat many more people much more quickly and, we trust, much less expensively,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University who was not involved in the research.Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as those who received a dummy pill.The study tracked 775 adults with mild-to-moderate COVID-19 who were considered high risk for severe disease because of health problems such as obesity, diabetes or heart disease. The results have not been reviewed by outside experts, the usual procedure for vetting new medical research.Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. After that time period, there were no deaths among those who received the drug, compared with eight in the placebo group, according to Merck.The results were so strong that an independent group of medical experts monitoring the trial recommended stopping it early.Company executives said they plan to submit the data to the FDA in the coming days.Even with the news of a potentially effective new treatment, experts stressed the importance of vaccines for controlling the pandemic, given that they help prevent transmission and also reduce the severity of illness in those who do get infected.Buzzsprout - Let's get your podcast launched! Start for FREEDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

El 1 de octubre, el laboratorio estadounidense Merck y Ridgeback Biotherapeutics anunciaron que su píldora antiviral experimental molnupiravir redujo en la mitad la probabilidad de hospitalización y muerte por covid-19 en personas recientemente infectadas con el virus. De confirmarse los resultados, el molnupiravir sería la primera píldora antiviral contra el SARS CoV2. El Dr. Elmer Huerta analiza en este episodio la repercusión que tendría este avance en la lucha contra la pandemia. Para conocer sobre cómo CNN protege la privacidad de su audiencia, visite CNN.com/privacidad

US equity markets retreated amid a fresh rotation out of technology stocks amid rising bond yields - Dow lost -324-points or -0.94%. Merck & Company Inc rose +2.09%, building on an +8.37% gain in last Friday's (1 October) session after the pharmaceutical major and partner Ridgeback Biotherapeutics said their oral antiviral treatment for COVID-19 reduced the risk of hospitalization or death by 50% for patients with mild or moderate cases. Merck is now planning to submit an application for an emergency use authorization for the treatment from the Food and Drug Administration and will also seek it from other regulatory bodies around the world. The broader S&P500 shed -1.30%, taking the index more than halfway to an official correction (defined as drop 10% from their most recent high). Information Technology (down -2.36%) and Communication Services (-2.11%) leading eight of the eleven primary sectors lower. The Energy sector (up +1.63%) was the leading primary sector performer, tracking strong gains on crude markets. Exxon Mobil Corp rose +1.30% and Conocophillips +1.98%. The Nasdaq lost -2.14%. Facebook Inc shed -4.89%, logging the worst single-day percentage decline since a -5% fall on 9 November, 2020 following a national broadcast of a whistleblower's allegations that the social media network placed profits before safety. The social media's woes were further compounded by a widespread outage of Facebook services, including Instagram and WhatsApp. Separately, Facebook filed a motion to dismiss the Federal Trade Commission's amended antitrust lawsuit against the company, saying the agency's complaint still lacked evidence Facebook violated antitrust laws. Elsewhere among major technology names, Apple Inc fell -2.46%, Amazon.com Inc -2.85%, Microsoft Corp -2.07% and Nvidia Corp -4.87%. However, Tesla Inc rose +0.81% after the company announced over the weekend that it had delivered 241,300 electric vehicles during the third quarter of 2021, topping analysts forecasts for the delivery of around 221K. The small capitalisation Russell 2000 lost -1.08%.

US equity markets retreated amid a fresh rotation out of technology stocks amid rising bond yields - Dow lost -324-points or -0.94%. Merck & Company Inc rose +2.09%, building on an +8.37% gain in last Friday's (1 October) session after the pharmaceutical major and partner Ridgeback Biotherapeutics said their oral antiviral treatment for COVID-19 reduced the risk of hospitalization or death by 50% for patients with mild or moderate cases. Merck is now planning to submit an application for an emergency use authorization for the treatment from the Food and Drug Administration and will also seek it from other regulatory bodies around the world. The broader S&P500 shed -1.30%, taking the index more than halfway to an official correction (defined as drop 10% from their most recent high). Information Technology (down -2.36%) and Communication Services (-2.11%) leading eight of the eleven primary sectors lower. The Energy sector (up +1.63%) was the leading primary sector performer, tracking strong gains on crude markets. Exxon Mobil Corp rose +1.30% and Conocophillips +1.98%. The Nasdaq lost -2.14%. Facebook Inc shed -4.89%, logging the worst single-day percentage decline since a -5% fall on 9 November, 2020 following a national broadcast of a whistleblower's allegations that the social media network placed profits before safety. The social media's woes were further compounded by a widespread outage of Facebook services, including Instagram and WhatsApp. Separately, Facebook filed a motion to dismiss the Federal Trade Commission's amended antitrust lawsuit against the company, saying the agency's complaint still lacked evidence Facebook violated antitrust laws. Elsewhere among major technology names, Apple Inc fell -2.46%, Amazon.com Inc -2.85%, Microsoft Corp -2.07% and Nvidia Corp -4.87%. However, Tesla Inc rose +0.81% after the company announced over the weekend that it had delivered 241,300 electric vehicles during the third quarter of 2021, topping analysts forecasts for the delivery of around 221K. The small capitalisation Russell 2000 lost -1.08%.

Carl Quintanilla, Jim Cramer and David Faber began the show with a look at Facebook under scrutiny: The company's former product manager Frances Haugen revealed her identity as the whistleblower who released a trove of internal Facebook research. She accuses the social media giant of allowing the spread of misinformation and putting profits ahead of the public good. Along with exploring what this all means for Facebook and its stock, the anchors reacted to what Haugen said about the company in a "60 Minutes" interview, as well as the response from Facebook itself. Carl, Jim and David also discussed news out of the auto sector: Shares of Tesla rise after Elon Musk's company announced it delivered more than 241-thousand vehicles during the third quarter, marking a quarterly record for the automaker. Ford posted a U.S. vehicle sales drop of 17.7% in September from a year ago, but added that reservations for its F-150 Lightning electric pickup truck have surpassed the 150,000 mark. Also in focus: Hedge fund Engine No. 1 announced its support for General Motors' goal to have a 100% electric car portfolio by 2035 -- as well as an investment in the automaker, Merck shares extend gains on news surrounding the experimental COVID pill it developed with partner Ridgeback Biotherapeutics -- while vaccine makers such as Moderna add to recent stock losses, what's sparking the latest jump in oil and natural gas prices, Qualcomm and an investment firm team up to buy a Swedish automotive tech company in a $4.5-billion deal, plus Jamie Dimon's take on bitcoin and regulating cryptocurrency.

U.S. President Biden received his booster shot of the Covid-19 vaccine on Monday, several days after the U.S. Food and Drug Administration cleared a booster developed by Pfizer and BioNTech for people 65 and older and certain other adults at high risk of severe illness. The 78-year-old president appealed to unvaccinated Americans to protect themselves against the virus. ————— Meanwhile, on Tuesday, Pfizer submitted research to the U.S. Food and Drug Administration on the effectiveness of its COVID-19 vaccine in children 5 to 11 years old but the shots may not be available until November. —————- Thousands of unvaccinated healthcare workers across the state of New York lost their jobs this week when a new vaccine mandate went into effect. This week, 593 United Airlines workers face dismissal for not complying with the requirement to get a Covid-19 vaccine. ———- Then on Wednesday, the US Centers for Disease Control and Prevention issued an urgent recommendation for pregnant women and those who have recently given birth to get vaccinated against coronavirus. Pregnant women are also urged to get flu shots. This warning from the CDC comes after 22 pregnant women died in August — the worst month yet of the pandemic. ————— On Thursday, news was announced of the first antiviral pill people can take at home to reduce by 50% their risk of winding up in the hospital or dying from the coronavirus. The pill is by pharmaceutical companies Merck and Ridgeback Biotherapeutics. These pills should not be taken as an alternative to vaccines. Pfizer and Roche, are also working on antiviral pills for patients already diagnosed with COVID-19. ————- On Friday, California Gov. Gavin Newsom announced that the state will require COVID-19 vaccines for all school children ages 12-17 once the FDA grants full approval, becoming the first state in the country to move forward on mandating vaccines for school children. The mandate will be implemented after January, when the next school term starts, and could come as late as July 2022, depending on when the FDA gives full approval for vaccines for kids under 16 years old. ———— Overseas, Japan came out of a coronavirus state of emergency on Thursday for the first time in more than six months as Covid-19 infections slowed. The emergency measures were in place for more than half of the country including Tokyo. ————- Still overseas, after eight years of planning and billions of dollars in spending, the Middle East's first ever World Fair opened on Friday in Dubai. Expo 2020 was postponed by a year due to the outbreak of the coronavirus. ———— Back in this country, a slow down in U.S. mail deliveries took effect Friday under a 10-year cost-cutting plan by the USPS chief. ————- And finally, the movie No Time To Die hit cinemas in the U.K. this week with the world premier at Royal Albert Hall, and opens in theaters Wednesday. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/sabah-fakhoury/message

(4:31) - Merck, in partnership with Ridgeback Biotherapeutics, has created an oral antiviral pill that proved extremely effective in a 800-person trial. The pill reduced hospitalizations and death due to COVID-19 in unvaccinated Americans by 50%.(12:56) -The ISM Manufacturing Index for September came in at 61.1, indicating that the manufacturing sector is growing. The index reading for August was 59.9.(23:42) - Consumer Spending rose 0.8% in August and personal income rose 0.2% for the month, both beating analyst expectations. Will spending by Americans continue to increase as COVID-19 cases slow and the holiday season approaches?(36:24) - LinkedIn is censoring certain profiles that contain negative sentiment regarding China. Why is LinkedIn asking users to self-censor on behalf of China?

Carl Quintanilla, Jim Cramer and David Faber kick off a new month and quarter by announcing details about Cramer launching the "CNBC Investing Club," which aims to help investors build long-term wealth. A big story out of Merck: The stock surging after the drug maker and its partner Ridgeback Biotherapeutics announced their experimental COVID-19 pill cut the risk of death and hospitalization by 50% in a late stage study. Both companies plan to file for emergency use authorization as soon as possible. Ridgeback Co-Founder Dr. Wayne Holman and Co-Founder and CEO Wendy Holman joined the program to discuss this big development in the war against the pandemic. Also in focus: Zoom Video and Five9 have terminated their nearly $15-billion deal by mutual consent, what to expect from the markets in the fourth quarter after a rough September, Exxon Mobil expects higher oil and gas prices to boost quarterly earnings by as much as $1.5-billion -- and Cathie Wood tweets about peak oil demand.

Merck and Ridgeback Biotherapeutics have developed a therapeutic pill for Covid that reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases. CNBC's Meg Tirrell reports that Merck hopes for emergency use authorization after “compelling results” in trials. Dr. Scott Gottlieb, former FDA commissioner, also discusses Merck's late-stage data and says it's a ‘profound game changer'. Billionaire investor Marc Lasry has resigned as chairman of Ozy Media, just three weeks to the day after he took the job, and less than a week since the digital news startup's deceptive marketing methods came to light. Ben Smith, the New York Times media columnist who broke the first story, discusses the Ozy drama. Facebook's global head of safety spoke to Instagram's impact on teenagers' mental health at a Senate subcommittee hearing. Senators compared Facebook to the tobacco industry for going after teens and children with a product they know is harmful to their health.In this episode:Ben Smith, @benytScott Gottlieb, @ScottGottliebMDMeg Tirrell, @megtirrellJoe Kernen, @JoeSquawkBecky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkin

這集podcast來談談新冠的口服藥物！ 新冠口服藥物懶人包 https://linshibi.com/?p=39749 1.針對早期輕、中度患者的居家口服藥，被視為終結對新冠恐懼的重要「解鎖關鍵」，成為疫苗之後的另一個需要超前部屬的場域。 2.現階段兩個重要治療藥物：單株抗體和瑞德西韋都需要靜脈注射治療，成本較高，藥物昂貴，在台灣多半需要住院才能給予。 若能如同流感一樣能有口服藥物，治療就會變得更容易普及，若在輕症階段就能投藥降低重症及死亡率，人們對新冠的恐懼感也會降低，也許是可以逐步恢復正常生活的關鍵。 3.根據生策會統計，全球有700多個新冠藥物進入二、三期臨床試驗。針對輕症防進展到重症的口服藥目前走在最前面的是默克，輝瑞、羅氏，已經在第三期臨床試驗收尾階段。 4.默克藥廠與Ridgeback Biotherapeutics 合作的口服藥molnupiravir原本是針對流感的藥物，後來發現對新冠也有效，能夠使病毒複製錯誤，以至病原體無法再繁殖。期望能降低病患體內的病毒量，縮短感染時間，避免後續的重症和死亡。 5.美國政府在今年6月早已超前部屬達成Molnupiravir採購協議，待該抗病毒藥物取得FDA緊急使用授權，將以12億美元購買170萬份療程。此外白宮也推動抗病毒藥物計劃(antiviral program for pandemics)，投入32億美金的經費。 6.值得一提的是，台灣七月開始便參與Molnupiravir的全球第三期臨床試驗，由台大醫院和部立桃園醫院做為臨床試驗地點，張上淳老師是計畫主持人。第三期臨床試驗結果預計在今年第四季出爐，一切順利的話可和FDA申請EUA，最快在今年底就可以量產。 7.口罩，檢驗，疫苗，最後是口服藥物。多管齊下，是否能讓人類戰勝疫情恢復比較正常的生活？這是不是最後一塊拼圖？讓我們拭目以待！ 日經新聞網：新冠口服藥最快年內問世，用藥方便易於量産 https://zh.cn.nikkei.com/industry/manufacturing/46157-2021-09-24-10-04-23.html 日經新聞網：口服藥或成為終結新冠疫情的關鍵 https://zh.cn.nikkei.com/politicsaeconomy/politicsasociety/46191-2021-09-28-05-03-00.html 全球逾700家競逐COVID-19新藥 口服藥備受期待 https://www.cna.com.tw/news/ahel/202109180034.aspx 新冠口服藥三期數據倒數 哪些藥廠可能成為世界救星？ https://www.cw.com.tw/article/5118284　 搶下新冠治療藥物先機　默沙東口服藥在台3期試驗這周啟動 https://www.upmedia.mg/news_info.php?SerialNo=118230 Delta變種病毒懶人包！ Podcast版 https://linshibi.pros.is/3pankg 部落格版 https://linshibi.com/?p=39717 各國分年齡的新冠致死率 https://linshibi.com/?p=35732 混打疫苗可行嗎？AZ混打輝瑞/BNT AZ混打莫德納等等 https://linshibi.com/?p=39613 給長輩的AZ疫苗懶人包 https://linshibi.com/?p=39590 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi Powered by Firstory Hosting

This is Coronavirus 411, the latest COVID-19 info and new hotspots… Just the facts… for June 4th, 2021. The United States sends its first shipments of surplus vaccine doses abroad today. 80 million doses by the end of June to start with. 75% of the first 25 million doses will be allotted through COVAX, the international distribution system to help with vaccinations in the world's poorest countries. California will fully reopen in less than two weeks and do away with almost all mask and social distancing requirements for the vaccinated people. But the California Occupational Safety and Health Standards Board is considering new workplace rules that even vaccinated employees must remain masked unless everyone in their workspace is inoculated. The California Chamber of Commerce is not pleased. We’re hearing a lot about vaccinations but what about effective treatments for COVID-19, and what about outright cures for it? The task is to develop a drug that targets the virus itself. So far, only one antiviral treatment — remdesivir — is recommended for use in the U.S., and experts say it’s not effective enough. A team at Miami’s Ridgeback Biotherapeutics began work in the spring of 2020 to find a possible treatment and get ready for the clinical trials. Now their drug, molnupiravir, is one of two medicines to treat COVID-19 nearing the end of clinical testing. Another report of inaccurate reporting. Two new studies show COVID-19 is many times more prevalent in Indonesia than shown by official figures. The inaccuracies are the result of a lack of testing and contact tracing. One study suggested 15% of Indonesians had already contracted COVID-19 - when official figures had infections at only around 0.4% of people. You’d think with all the lockdowns and working from home U.S. traffic deaths would have dropped tremendously. Not at all. In fact, the National Highway Traffic Safety Administration says traffic deaths rose 7% last year, the biggest increase in 13 years. The agency blamed it on drivers taking more risk because roads were less congested. In the United States cases were down 46%, deaths are down 35%, and hospitalizations are down 22% over 14 days. The 7-day average of new cases has been trending down since April 14. There are now 5,537,566 active cases in the United States. The current top 5 states by number of active cases: California, Virginia, Maryland, Kentucky, and New York. The top 10 counties with the highest number of recent cases per capita according to The New York Times: Chattahoochee, GA. Livingston, MO. Linn, MO. Dimmit, TX. Karnes, TX. Lincoln, WA. Moffat, CO. Tyler, TX. Reeves, TX. And LaSalle, LA. There have been 596,401 deaths in U.S. recorded as Covid-related, with a current national fatality rate of 1.8%. The states with the most new deaths reported as COVID-related: Michigan 62. Texas 57. Florida 49. Pennsylvania 34. Georgia 33. Oklahoma 25. Illinois 24. Washington 23. California 22. And Alabama 21. The top 3 vaccinating states by percentage of population that’s had at least one dose, Vermont at 70.7%, Hawaii at 66.9%, and Massachusetts at 66.7%. The bottom 3 vaccinating states are Mississippi at 34.3%, Louisiana at 35.9%, and Alabama at 36.1%. The percentage of the U.S. that’s been fully vaccinated is 41%. Globally, cases were down 27% and deaths down 12% over 14 days, with the 7-day average trending down since May 28. There are now 13,573,286 active cases around the world. The five countries with the most new cases: India 131,371. Brazil 83,391. Argentina 32,291. Colombia 28,624. And the United States 17,821. There have now been 3,698,371 deaths reported as Covid-related worldwide. For the latest updates, subscribe for free to Coronavirus 411 on your podcast app or ask your... See acast.com/privacy for privacy and opt-out information.